While PARP‐1 inhibitors have currently no role in the treatment of CCA, the potential influence of SNPs on PARP‐1 function does implicate further investigations in the interaction of SNPs, PARP activity and PARP‐1 inhibitors. Here, PARP1 is linked to cholangiocarcinoma.